Lymphoma development and survival in refractory coeliac disease type II:Histological response as prognostic factor

Autor: Cjj Mulder, Otto Visser, Birgit I. Witte, Nicolette J. Wierdsma, Hetty J. Bontkes, T van Gils, Gerd Bouma, G.J. Tack, Rlj van Wanrooij, Petula Nijeboer

Publikováno v: Nijeboer, P, van Wanrooij, R L J, van Gils, T, Wierdsma, N J, Tack, G J, Witte, B I, Bontkes, H J, Visser, O, Mulder, C J J & Bouma, G 2017, ' Lymphoma development and survival in refractory coeliac disease type II : Histological response as prognostic factor ', United European Gastroenterology Journal, vol. 5, no. 2, pp. 208-217 . https://doi.org/10.1177/2050640616646529
United European Gastroenterology Journal, 5(2), 208-217. SAGE Publications Inc.

Background: Refractory coeliac disease type II (RCDII) frequently transforms into an enteropathy-associated T-cell lymphoma (EATL) and therefore requires intensive treatment. Current evaluated treatment strategies for RCDII include cladribine (2-CdA)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee7dea832b8aef00d8b195ae9a20aef
https://research.vumc.nl/en/publications/e7d5e080-1130-4863-a1a5-a9b07c2c085d